ERBB2 and breast carcinoma: HER2-low breast cancers, defined as IHC 1+ or 2+ with negative in situ hybridization (ISH), represent approximately 50% of HER2-negative cases and have demonstrated sensitivity to HER2-targeted antibody-drug conjugates (ADCs) [2].